Table 1 GFs employed in pre-clinical trials.
Name | Advantage | Treating diseases |
|---|---|---|
NGF | • Essential for neural regeneration and neurotrophic function | Diabetic peripheral neuropathy [139] Peripheral nerve injury [124] |
FGF1 | • Classic mitogenic and neuroprotective activities | Diabetes mellitus [140] Diabetic nephropathy [141] |
FGF2 | • Angiogenesis • Stimulating cell proliferation, migration, and differentiation | Wound healing [142] Diabetic foot [143] Spinal cord injury [144] |
FGF21 | • Facilitating glucose and lipid intake • Improving insulin sensitivity • Metabolic regulator | Obesity [145] Hyperlipidemia [146] Alcohol-induced hepatic steatosis [147] |
NT-3 | • Regulation of axonal and dendritic outgrowth, synapse formation and function • Promoting neuronal survival Enhancing neurite growth and axonal regeneration | Traumatic brain inury [148] Spinal cord injury [149] |
BDNF | • Synapsis plasticity • Neuronal survival • Formation of new synapses | Depression [150] Metabolic disorders [151] |
PDGF | • Modulation of neurogenesis, cell survival and synaptogenesis | Tumorigenesis [152] Alzheimer disease [153] |
